Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Varicella Two-Dose Vaccination Recommended For Teens And Older Cohorts

Executive Summary

Two-dose varicella vaccination for persons ages 13 years and older without evidence of immunity is recommended by the Centers for Disease Control & Prevention Advisory Committee on Immunization Practices

You may also be interested in...



ACIP In Brief

Gardasil catches catch-up population: Merck's human papillomavirus vaccine Gardasil should be administered to females 13 to 26 years of age as part of a catch-up program and to girls ages 11 and 12 as a routine vaccination, the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices unanimously agreed June 29 in Atlanta. Published estimates of cost-effectiveness ratios for vaccination of 12-year-old females range from $14,600 to $24,300 per quality adjusted life-year. Panel members supported use of the quadrivalent vaccine in "special situations" for females that would normally not be vaccinated, including those with abnormal pap tests, genital warts, positive HPV tests, immunosuppression and who are lactating. The committee agreed that women found to be pregnant after receiving the initial dose of vaccination should delay completion of series until after pregnancy. Gardasil cleared FDA June 8 for prevention of cervical cancer and pre-cancers (1"The Pink Sheet" June 12, 2006, p. 3)...

ACIP In Brief

Gardasil catches catch-up population: Merck's human papillomavirus vaccine Gardasil should be administered to females 13 to 26 years of age as part of a catch-up program and to girls ages 11 and 12 as a routine vaccination, the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices unanimously agreed June 29 in Atlanta. Published estimates of cost-effectiveness ratios for vaccination of 12-year-old females range from $14,600 to $24,300 per quality adjusted life-year. Panel members supported use of the quadrivalent vaccine in "special situations" for females that would normally not be vaccinated, including those with abnormal pap tests, genital warts, positive HPV tests, immunosuppression and who are lactating. The committee agreed that women found to be pregnant after receiving the initial dose of vaccination should delay completion of series until after pregnancy. Gardasil cleared FDA June 8 for prevention of cervical cancer and pre-cancers (1"The Pink Sheet" June 12, 2006, p. 3)...

Merck ProQuad Clears FDA; MMR/V Vaccine Will Begin Shipping In Weeks

FDA's Sept. 6 clearance of Merck's measles, mumps, rubella and varicella vaccine ProQuad covers primary and second-dose use of the vaccine

Related Content

Topics

UsernamePublicRestriction

Register

PS046066

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel